Home › Crohn's Disease › Iowa › Des Moines
Crohn's Disease clinical trials in Des Moines, IA
3 studies for Crohn's Disease are looking for participants at sites in and around Des Moines (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
RecruitingPhase 3
- Iowa Digestive Disease Center ( Site 5007), Clive · 6 mi away
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- Heartland Medical Research Inc, Clive · 6 mi away
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- Heartland Medical Research, Inc.-Site Number: 8400134, Clive · 6 mi away
About Crohn's Disease
Crohn's Disease can cause inflammation in any area from the mouth to the anus. Read about medicines, surgery or dietary management to treat symptoms.
More about Crohn's Disease on MedlinePlus
Crohn's Disease trials in other cities
- New York City, NY33 studies
- St. Louis, MO19 studies
- Miami, FL19 studies
- Orlando, FL19 studies
- Boston, MA18 studies
- Houston, TX17 studies
- Atlanta, GA16 studies
- Tyler, TX16 studies
- San Diego, CA15 studies
- Cleveland, OH15 studies
- Colorado Springs, CO14 studies
- San Antonio, TX14 studies
Other studies in Des Moines
- Non-Small Cell Lung Cancer10 studies
- Breast Cancer9 studies
- Lung Cancer9 studies
- Colorectal Cancer8 studies
- Chronic Lymphocytic Leukemia8 studies
- Overweight7 studies
- Obesity6 studies
- Multiple Myeloma6 studies
- Bladder Cancer6 studies
- Type 2 Diabetes5 studies
- Cardiovascular Disease5 studies
- Burkitt Lymphoma5 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.